What is the share price of Polar Pharma India Ltd (523333)?

Company share prices are keep on changing according to the market conditions. The current trading price of Polar Pharma India Ltd (523333) on 01-Jan-1970 05:30:00 at 05:30 is .

What is the P/E ratio of Polar Pharma India?

The latest standalone P/E ratio of Polar Pharma India as of 01-Jan-1970 is 0.00.

What is the P/B ratio of Polar Pharma India Ltd (523333)?

The latest standalone P/B ratio of Polar Pharma India Ltd (523333) as of 01-Jan-1970 is -0.01.

What is the 52-week high and low of Polar Pharma India Ltd (523333)?

The 52-week high of Polar Pharma India Ltd (523333) is Rs. 0.82 and the 52-week low is Rs. 0.82.

Polar Pharma India Ltd (523333) Share Analysis – Quality, Growth & Valuation Zone & DeciZen Rating

Name: Polar Pharma India Ltd (523333)
Brand: Polar Pharma India

Polar Pharma India Ltd (523333)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 523333 NSE: Rubber Products | Small Cap | Polar Pharma India Share Price

Polar Pharma India Ltd (523333)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 523333 NSE: Rubber Products | Small Cap | Polar Pharma India Share Price

Key Metrics

Valuation Multiples

Market Cap

₹1 Cr.

Current Price

₹0

52-Week Low / High

₹1 / 1

TTM EPS

₹-16.6

TTM Sales

₹9.4 Cr.

Book Value per Share

₹-103.6

P/E Ratio

0.00

Industry PE

27.6

Price to Book (P/B)

-0.01

Price to Sales (P/S)

0.11

EV/EBITDA

-64.09

Dividend Yield

NAN%

Profitability Efficiency

Return on Equity (ROE)

0.00%

Return on Capital Employed (ROCE)

-20.34%

Return on Assets (ROA)

-69.05%

Operating Profit Margin

-12.5%

Net Profit Margin

-116.64%

Gross Profit Margin

-102.8%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

48.49%

Operating Profit Growth (1 Year)

-205.73%

Net Profit Growth (1 Year)

Asset Quality

Promoter Holding

29.75%

Pledged shares (%) of Promoter's holding (%)

93.93%

Reserves

₹-139 Cr.

Equity

₹12.3 Cr.

Face Value

₹10

All Time Low / High

₹0.79 / 80.00

Polar Pharma India stock performance

Key Ratios

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	TTM
ROCE % ⓘ	6%	9.6%	3%	26.5%	-17.3%	-3.8%	-176.2%	-21.1%	-0.9%	-20.3%	-
Growth Parameters ⓘ
Sales ⓘ	49.1	43.3	35.2	46	18.9	25.9	0.3	0	10.9	16.2	9
Sales YoY Gr.	-	-11.8%	-18.8%	30.9%	-59%	37%	-99%	-88.5%	36,266.7%	48.5%	-
Adj EPS ⓘ	0	0.1	-4.4	-6.8	-5.3	-1.8	-30.5	-13.1	-11	-15.4	-16.6
YoY Gr.	-	550%	-3507.7%	NA	NA	NA	NA	NA	NA	NA	-
BVPS (₹) ⓘ	6.2	6.6	2.6	9.1	2.9	0.8	-54.6	-67.7	-78.7	-94.1	-103.6
Adj Net Profit ⓘ	0	0.2	-5.3	-8.3	-6.5	-2.3	-37.4	-16.1	-13.5	-18.9	-20
Cash Flow from Ops. ⓘ	3.6	-0.4	3.8	20.5	-6.4	6.1	-40.5	2.4	-0.9	0.7	-
Debt/CF from Ops. ⓘ	14.6	-138.2	14.8	1.9	-7	6.8	-2.1	43	-128	194.4	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-11.6%	-3%	296.4%	48.5%
Adj EPS ⓘ	-309.3%	NA	NA	NA
BVPSⓘ	-235.2%	-300.8%	NA	NA
Share Price	-	-	-	-

Key Financial Parameters ⓘ

	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	TTM
Return on Equity % ⓘ	0.2	1.4	-67	-92.3	-74.1	-64.2	117.8	21.8	15.3	18.1	16.8
Op. Profit Mgn % ⓘ	6	14.9	10.5	-13.7	-21.3	1	-4123.7	-7462.1	17.6	-12.5	-20.2
Net Profit Mgn % ⓘ	0.1	0.4	-15.1	-18.1	-34.5	-8.7	-14530.6	-58751.4	-123.7	-116.7	-217.1
Debt to Equity ⓘ	6.1	5.9	12.8	3.2	9.4	18.6	-1.3	-1.3	-1.2	-1.2	-
Working Cap Days ⓘ	215	248	295	230	552	281	14,043	67,295	223	134	23
Cash Conv. Cycle ⓘ	130	156	203	174	445	210	7,468	7,812	4	24	-546

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12
Sales	49.10	43.29	35.17	46.02	18.87	25.85	0.26	0.03	10.91	16.20
Operating Expenses ⓘ +	46.18	37.30	31.58	52.81	23.20	26.10	11.24	2.11	8.99	18.23
Manufacturing Costs	5.72	4.28	4.02	10.83	3.88	2.85	0.36	0.05	2.64	3.16
Material Costs	26.57	19.51	18.59	27.33	10.12	15.38	2.28	0.04	3.52	8.38
Employee Cost	4.27	4.49	4.73	6.07	5.32	4.89	2.95	0.25	1.68	3.76
Other Costs ⓘ	9.62	9.02	4.24	8.57	3.88	2.98	5.65	1.77	1.15	2.93
Operating Profit ⓘ	2.92	5.99	3.59	-6.80	-4.33	-0.25	-10.98	-2.08	1.92	-2.03
Operating Profit Margin (%)	5.9%	13.8%	10.2%	-14.8%	-23.0%	-1.0%	-4,269.7%	-7,622.6%	17.6%	-12.5%
Other Income ⓘ +	2.64	1.99	0.92	2.69	1.76	0.86	1.89	0.12	0.15	0.21
Exceptional Items ⓘ	0	0	0	21.65	-3.49	0	-44	0	-0.04	0.02
Interest ⓘ	2.73	6.44	7.90	3.20	4.76	5.24	3.87	11.85	13.33	14.85
Depreciation ⓘ	1.93	1.96	2.66	2.73	2.74	2.40	2.33	2.28	2.23	2.25
Profit Before Tax ⓘ	0.89	-0.42	-6.06	11.61	-13.57	-7.04	-59.29	-16.10	-13.53	-18.90
Tax ⓘ	0.85	-0.26	-0.70	5.12	-4.52	-4.47	8.64	0	0	0
Profit After Tax	0.04	-0.16	-5.36	6.48	-9.05	-2.57	-67.93	-16.10	-13.53	-18.90
PAT Margin (%)	0.1%	-0.4%	-15.2%	14.1%	-48.0%	-9.9%	-26,418.2%	-58,863.7%	-124.0%	-116.0%
Adjusted EPS (₹)	0.0	-0.1	-4.5	5.3	-7.4	-2.1	-55.4	-13.1	-11.0	-15.4
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Polar Pharma India - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12
Equity and Liabilities
Shareholders Fund +	10.76	10.60	5.24	12.77	4.78	2.24	-65.69	-81.79	-95.32	-114.22
Share Capital ⓘ	13.22	13.22	13.22	13.52	13.52	13.52	13.52	13.52	13.52	13.52
Reserves ⓘ	-2.46	-2.62	-7.98	-0.75	-8.74	-11.28	-79.21	-95.31	-108.84	-127.74
Debt +	52.69	54.58	55.69	39.58	44.91	41.68	84.68	102.99	117.17	132.16
Long Term Debt	52.69	54.58	55.69	39.58	44.91	41.68	84.68	102.99	0.02	0
Short Term Debt	0	0	0	0	0	0	0	0	117.15	132.16
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	7.79	7.45	4.83	7.16	1.46	0.85	0.85	2.26	3.34	1.56
Others Liabilities ⓘ	-1.79	-2.30	-2.48	8.73	6.33	0.04	12.35	5.32	5.73	4.32
Total Liabilities ⓘ	69.45	70.33	63.27	68.24	57.48	44.81	32.18	28.78	30.92	23.82
Fixed Assets
Net Fixed Assets ⓘ +	25.12	37.05	34.82	33.86	31.10	28.86	26.13	23.80	21.61	19.40
Gross Block	38.15	52.04	52.32	54.03	53.83	53.64	52.11	51.95	51.99	51.97
Accumulated Depreciation	13.03	14.99	17.50	20.17	22.73	24.78	25.97	28.15	30.37	32.57
CWIP ⓘ	10.34	0.01	0.27	0.02	0	0	0	0	0	0
Investments ⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	15.99	20.64	14.83	17.04	12.71	3.49	0.69	0.46	3.52	1.48
Trade Receivables	9.65	7.36	10.36	12.56	9.84	6.38	0.03	0.03	1.75	0.16
Cash Equivalents	3.68	1.41	0.88	2.46	0.81	1.73	0.48	0.46	0.50	1.35
Others Assets ⓘ	4.67	3.86	2.12	2.29	3.02	4.35	4.86	4.03	3.53	1.44
Total Assets ⓘ	69.45	70.33	63.27	68.24	57.48	44.81	32.18	28.78	30.92	23.82

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12
Cash Flow From Operating Activity ⓘ +	3.62	-0.40	3.77	20.50	-6.41	6.12	-40.49	2.39	-0.92	0.68
PBT ⓘ	0.89	-0.42	-6.06	-10.04	-10.08	-7.04	-15.29	-16.10	-13.53	-18.90
Adjustment ⓘ	4.88	8.69	10.64	5.53	6	6.67	5.34	14.55	15.33	18.25
Changes in Working Capital ⓘ	0.54	-2.84	1.91	3.81	1.09	6.55	13.83	3.94	-2.71	1.34
Tax Paid ⓘ	0	0	0	-0.45	0.07	-0.06	-0.38	0	0	-0.01
Cash Flow From Investing Activity ⓘ +	-4.40	-3.57	-0.73	-1.21	0.97	0.62	0.38	0.01	-0.05	0.05
Capex	-2.76	-3.57	-0.73	-1.71	0.22	-0.09	0.08	0.01	-0.05	-0.04
Net Investments	0	0	0	0	-0	0	0	0	0	0
Others ⓘ	-1.65	0	0	0.50	0.75	0.71	0.30	0	0	0.09
Cash Flow From Financing Activity ⓘ +	2.97	1.62	-3.58	-17.71	3.89	-5.78	39.14	-2.42	0.98	0.18
Net Proceeds from Shares ⓘ	0.86	0	0	1.05	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	3.94	-5.51	0	0	0	0
Interest Paid ⓘ	0	0	0	-8.07	-1.10	-0.27	-3.86	-11.84	-13.21	-14.81
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	2.11	1.62	-3.58	-10.69	1.05	0	42.99	9.42	14.19	14.99
Net Cash Flow ⓘ	2.18	-2.35	-0.53	1.58	-1.55	0.96	-0.98	-0.02	0.02	0.92

Financial Ratio

PARTICULARS	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12
Ratios
ROE (%)	0.53	-2.08	-97.02	91.16	-123.55	-113.6	N/A	N/A	N/A	N/A
ROCE (%)	5.98	9.62	2.98	26.45	-17.33	-3.84	N/A	N/A	N/A	N/A
Asset Turnover Ratio	0.72	0.62	0.53	0.7	0.3	0.51	0.01	0	0.37	0.59
PAT to CFO Conversion(x)	90.5	N/A	N/A	3.16	N/A	N/A	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	91.30	71.70	92	90.90	216.60	114.50	4,544.30	350.90	29.80	21.50
Inventory Days	103.30	154.40	184	126.40	287.80	114.40	2,963.90	7,634.10	66.50	56.30
Payable Days	110	142.50	120.60	80	155.30	27.40	136.30	0	290.70	106.80

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

93.93

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Polar Pharma India Ltd FAQs

The current trading price of Polar Pharma India on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Polar Pharma India stood at ₹1.01 Cr

The latest P/E ratio of Polar Pharma India as of 31-Dec-1969 is 0.00.

The latest P/B ratio of Polar Pharma India as of 31-Dec-1969 is -0.01.

The 52-week high of Polar Pharma India is ₹0.82 and the 52-week low is ₹0.82.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Polar Pharma India is ₹9.38 ( Cr.) .

Data is not available for this company.

No data found

About Polar Pharma India Ltd

Polar Pharma India, earlier known as â€˜Palar Latex Ltd, was launched in the year 1988 and starterd the commercial production from its Balasore plant in 1991.

The company is committed to better, safer, more enjoyable life for the people. A company where people and technology continuously work hand in hand to evolve new standards of excellence in the field of male prophylactics. Where business values are re-defined with greater, global social concerns in mind. And the concern is turned into an action point in the companyâ€™s mission statement itself.

Today, Polar Pharma enjoys worldwide popularity and trust, as the key producer of high quality, male latex prophylactics in India. In fact, the company is one of the largest private sector condom manufacturing units in Asia, with an installed capacity of over 700 million pieces per annum.

A qualified team of professionals conduct regular checks for every batch produced to ensure consistency and quality of the finished products. PPIL has an in-house fully equipped product testing laboratory for quality checks

Product range of the company includes:

Contraceptives â€“ condoms of the following types:

Adam- Lubricated Condoms
Seorita
Moments- Premium Condoms

Achievements/ recognition :

The companyâ€™s quality System has ISO:9001 accreditation received in the year 2000. and ISO 14001
The company has also received CE Certification in the year 2003.
Capexil Awards 2000-2001, 2002-2003 & 2005-2006
Capexil Certificate
Star House Awards

Polar Pharma India Ltd (523333)

Polar Pharma India Ltd (523333)

Polar Pharma India stock performance

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Polar Pharma India - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Polar Pharma India Ltd FAQs

About Polar Pharma India Ltd

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Polar Pharma India Ltd (523333)

Polar Pharma India Ltd (523333)

Polar Pharma India stock performance

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Polar Pharma India - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Polar Pharma India Ltd FAQs

What is the share price of Polar Pharma India?

What is the market cap of Polar Pharma India?

What is the P/E ratio of Polar Pharma India?

What is the P/B ratio of Polar Pharma India?

What is the 52-week high and low of Polar Pharma India?

What is the TTM revenue of Polar Pharma India?

Is a good quality company?

Is undervalued or overvalued?

Is a good buy now?

About Polar Pharma India Ltd

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.